EMA/178693/2020

European Medicines Agency decision

P/0177/2020

of 15 May 2020

on the acceptance of a modification of an agreed paediatric investigation plan for dimethyl fumarate (Tecfidera), (EMEA-000832-PIP01-10-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

European Medicines Agency decision

P/0177/2020

of 15 May 2020

on the acceptance of a modification of an agreed paediatric investigation plan for dimethyl fumarate (Tecfidera), (EMEA-000832-PIP01-10-M05) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004[1],

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency[2],

Having regard to the European Medicines Agency's decision P/76/2011 issued on 5 April 2011, the decision P/0027/2013 issued on 26 February 2013, the decision P/0144/2015 issued on 10 July 2015, the decision P/0132/2016 issued on 20 May 2016 and the decision P/0167/2017 issued on 30 June 2017,

Having regard to the application submitted by Biogen Idec Ltd. on 19 December 2019 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 27 March 2020, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.

(2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

[1] OJ L 378, 27.12.2006, p.1.
[2] OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for dimethyl fumarate (Tecfidera), capsule, hard, oral use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Biogen Idec Ltd., Innovation House, 70 Norden Road, SL6 4AY – Maidenhead, United Kingdom.

EMA/PDCO/14795/2020
Amsterdam, 27 March 2020

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan

EMEA-000832-PIP01-10-M05

Scope of the application

Active substance(s):

Dimethyl fumarate

Invented name:

Tecfidera

Condition(s):

Treatment of multiple sclerosis

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Capsule, hard

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Biogen Idec Ltd.

Information about the authorised medicinal product:

See Annex II

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Biogen Idec Ltd. submitted to the European Medicines Agency on 19 December 2019 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/76/2011 issued on 5 April 2011, the decision P/0027/2013 issued on 26 February 2013, the decision P/0144/2015 issued on 10 July 2015, the decision P/0132/2016 issued on 20 May 2016 and the decision P/0167/2017 issued on 30 June 2017.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 28 January 2020.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:

   - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

   The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

1.1. Condition: treatment of multiple sclerosis

The waiver applies to:

- the paediatric population from birth to less than 10 years of age;
- capsule, hard, oral use;
- on the grounds that the specific medicinal product does not represent a significant therapeutic benefit as clinical studies(s) are not feasible.

2. Paediatric Investigation Plan

2.1. Condition: treatment of multiple sclerosis

2.1.1. Indication(s) targeted by the PIP

Treatment of relapsing remitting forms of multiple sclerosis.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 10 to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Hard capsule

2.1.4. Measures

Area	Number of measures	Description
Quality	0	Not applicable.
Non-clinical	1	**Study 1:** Juvenile toxicology study in male rats
Clinical	1	**Study 2:** Open-label, randomised, multicentre, multiple dose, active controlled, parallel-group efficacy and safety study of dimethyl fumarate in children from 10 to less than 18 years of age with relapsing-remitting multiple sclerosis. (Part 1)

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By January 2021
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Multiple Sclerosis

Authorised indication(s):

- Tecfidera is indicated for the treatment of adult patients with relapsing remitting multiple sclerosis

Authorised pharmaceutical form(s):

Gastro-resistant hard capsule

Authorised route(s) of administration:

Oral route